The MyLungHealth randomized trial found that digital tools improved eligibility assessment and CT ordering for #LungCancer screening, but gains in scan completion were limited. ja.ma/48QffoY

Among over 7000 patients with #cancer, higher baseline fatigue before systemic therapy was linked to an increased risk of severe, life-threatening, and fatal adverse events. ja.ma/4qmZtrt

Viewpoint: GLP-1 receptor agonists induce weight loss but may lead to pronounced muscle mass reduction, raising concerns for patients with cancer at risk of frailty and decreased physical function. ja.ma/4qbD8O9

During nationwide platinum shortages, #oncologists maintained overall platinum use for nonmetastatic lung cancer and substituted immunotherapy when treating metastatic cases, closely following national guidance. ja.ma/4qiLZwS

Viewpoint: The recommendation against hormonal contraception for premenopausal women at risk for or surviving breast cancer while taking tamoxifen is based on limited evidence, underscoring the need for more targeted research. ja.ma/3MPoIEs

The numbers are in. The numbers are in. This year's most popular JAMA Network content spans a range of topics, from #fluoride to #Parkinson disease to #GLP-1s. What was your favorite article in 2025 -- and did other readers agree? 🔗 ja.ma/4sbDfKO

Ductal carcinoma in situ (DCIS) score profiling after breast-saving surgery enabled selective radiotherapy, allowing half of women with DCIS to safely avoid radiotherapy while maintaining low 5-year in-breast recurrence rates for all risk groups. ja.ma/498WNXG

Editorial: Cardiac surveillance recommendations after breast cancer treatment remain limited, with evidence suggesting most survivors benefit from primary care focused on prevention and management of traditional cardiovascular risk factors. ja.ma/4jbyOLW

Breast cancer risk for pathogenic variant carriers is substantially higher with a first-degree family history, and risk estimates vary by gene, family history, and other factors, guiding personalized screening and prevention decisions. ja.ma/4pPMpLB

Head and neck #cancer is the seventh most common cancer worldwide. This @jama.com Review summarizes the epidemiology, clinical presentation, diagnosis, and treatment of head and neck squamous cell carcinomas (#HNSCC) of the upper aerodigestive tract. ja.ma/4pSSyXe

Immune checkpoint inhibitors are independently linked to increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis, with additive effects observed when combined with high-risk drugs. ja.ma/3MMrWIT

Heart radiation therapy, high-dose anthracyclines, and platinum agents were linked with increased risk of symptomatic valvular heart disease, especially at higher doses and longer follow-up. ja.ma/4qjS7Fh

💬 Viewpoint: Nonfinancial conflicts, including relationships and beliefs, can shape #Oncology research outcomes, highlighting the need for routine disclosure and management to support scientific credibility. ja.ma/496w0LD

Viewpoint: Proposed use of credit screening in clinical settings could enable rapid detection of financial risk at cancer diagnosis, with automated analysis guiding early financial counseling and support. ja.ma/4oYMWJF

📢 This Special Communication describes obstacles to sharing data and biospecimens and proposes strategies to enhance access and collaboration. ja.ma/494xV37

Quadrivalent #HPV vaccination was associated with lower rates of high-grade vulvovaginal lesions, especially among women vaccinated at ages 10 to 16, in a large cohort study. ja.ma/3L9UrQ9

#AI technologies hold potential to enhance acute myeloid leukemia management by improving risk stratification, early detection, and treatment optimization through integration of clinical, morphological, and genetic data. ja.ma/4j0UPNk

In a pooled analysis of patients from 15 phase 3 trials, the risk of #coloncancer recurrence after surgery and adjuvant #chemotherapy fell below 0.5% by 6 years. ja.ma/4pPtUXG

Hugely impactful work addressing the toughest of diagnoses - leptomeningeal disease. Early trial discontinuation due to significant benefit of proton craniospinal irradiation (pCSI). Kudos to the authors including @drbetofmdphd.bsky.social @stanford-cancer.bsky.social 🙏🧠

A new study by @ucdaviscancer.bsky.social scientists highlight the urgent need to identify and address survivorship needs for young cancer survivors. @ucdavishealth.bsky.social @jamaoncology.com @hcai-ca.bsky.social health.ucdavis.edu/cancer/news/...

Sarcomas comprise a heterogeneous group of malignant neoplasms that include genomically simple and genomically complex subtypes. This consensus provides guidelines for efficient, rational use of next-generation sequencing in their clinical management. ja.ma/4qhwTb7

#AI-detected tumor-infiltrating lymphocytes in pretreatment metastatic melanoma specimens were associated with response to ICI, improved progression-free survival, and improved overall survival. ja.ma/4ahCjhs

A phase 2 trial demonstrated an isotoxic improvement in #cancer control with prostate-specific membrane antigen positron emission tomography-guided intensification of salvage RT after radical prostatectomy. ja.ma/48P70YX

💬 Viewpoint: Effective stroke care for patients with cancer requires rapid interdisciplinary communication, clear documentation of prognosis and goals of care, and urgent application of acute stroke therapies. ja.ma/48PwjKl

In a JAMA #RCT presented at #SABCS25, researchers found risk-based breast cancer screening was as safe as annual screening for detecting advanced cancers but did not reduce breast biopsy rates. @sabcs.bsky.social ja.ma/4oPPREA

Definitive radiotherapy with or without chemotherapy in anterior nasal cavity cancers achieved high rates of long-term organ preservation & favorable local recurrence rates for patients who declined rhinectomy or had unresectable disease. ja.ma/48MYOIH

In this secondary analysis of the RxPONDER trial, chemoendocrine therapy was associated with greater and more persistent self-reported cognitive impairment than endocrine therapy alone in both pre- and postmenopausal women with #BreastCancer. ja.ma/4oRwGdF

💬 Editorial: Cancer-related cognitive impairment frequently affects #BreastCancer survivors and may persist for years after treatment, with greater risk among those receiving chemoendocrine therapy. ja.ma/4rPjvfT

Viewpoint: @fda.gov analysis of primary clinical trial data frequently uncovers risks and flaws not apparent in published studies, highlighting the importance for clinicians to consider these regulatory insights in their treatment decisions. ja.ma/44PfzSg

A 400-mg ribociclib starting dose did not match the efficacy of 600 mg in HR+/ERBB2− advanced breast cancer, but had similar progression-free survival and fewer adverse events. ja.ma/48z6XR4

This JAMA Oncology Patient Page describes the 3 main types of urinary diversions and care required after surgery to ensure an active and fulfilling life. ja.ma/4pGXEVS

A prediction model incorporating clonal hematopoiesis and other factors identified substantial heterogeneity in the cancer-preventive effect of low-dose aspirin among older adults. ja.ma/47Rhuba

💬 Editorial: Precision adjuvant therapy for stage III #ColonCancer may be enhanced through molecular profiling for ctDNA status and PIK3CA mutation, informing use of celecoxib or aspirin alongside standard treatment. ja.ma/4iLrk28

ctDNA status may help identify which patients benefit from adjuvant celecoxib, supporting personalized treatment approaches in #ColonCancer. ja.ma/4rBs9yn

Viewpoint explores the growing complexity of #cancer care and the essential role of #AI-enhanced decision support tools in helping oncologists manage evolving treatment options and maintain high-quality patient care. ja.ma/3XFOOM8

Many elevated PSA levels normalize within a year, but consistently high values warrant direct diagnostic evaluation without repeated testing. ja.ma/4p98tAk

Among adolescents and young adults with #cancer, 9.5% of patients with earlier-stage cancer experienced metastatic recurrence within five years, with the highest rates in sarcoma (24.5%) and colorectal cancer (21.8%). ja.ma/3XX4oTH

Specific oral bacteria and fungi were risk factors for pancreatic cancer development, suggesting the potential use of oral microbiota as noninvasive biomarkers for identifying high-risk individuals. ja.ma/48iyZjt

More young people are now being diagnosed with lung cancer than in the past. This JAMA Oncology Patient Page describes causes, types, and symptoms of lung cancer in people younger than 50 years and how it can be treated. ja.ma/4olHz70

Among adolescents and young adults with #cancer, 9.5% of patients with earlier-stage cancer experienced metastatic recurrence within five years, with the highest rates in sarcoma (24.5%) and colorectal cancer (21.8%). ja.ma/3XQMbHr

Despite high insurance coverage rates, individuals diagnosed with #cancer in Massachusetts experienced increases in medical debt, with those having bladder and colorectal cancer facing additional increases. ja.ma/3XSnYk0

Pembrolizumab combined with platinum-based chemotherapy showed a 39.4% response rate and manageable toxicity as a potential first-line treatment for advanced penile squamous cell carcinoma. ja.ma/3KnGEVO

On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new @who.int guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/43V8C1I

Among adolescents and young adults with #cancer, 9.5% of patients with earlier-stage cancer experienced metastatic recurrence within five years, with the highest rates in sarcoma (24.5%) and colorectal cancer (21.8%). ja.ma/4rnNKdt

In early 2025, the National Cancer Institute terminated 181 extramural grants, totaling more than $640 million in awards. Terminations targeted primarily basic science, general oncology, and early-career investigators. ja.ma/3LTwhto

With an estimated 1.8 million deaths annually, primary lung cancer is the leading cause of cancer-related deaths. This Review discusses the controversies and challenges in the treatment of synchronous oligometastatic NSCLC without an AGA. ja.ma/4obHPFz

Phase 2 trial finds lorlatinib yielded a 73% objective response rate and median progression-free survival of 53.6 months in TKI-naive advanced ROS1-positive NSCLC. ja.ma/3XeWTrb

Patient-reported outcomes, such as higher health status and lower symptom burden, are independently associated with improved overall survival in cancer patients. ja.ma/4rrb22o

Metastatic recurrence continues to be a leading cause of morbidity and mortality among patients with solid tumors. Listen to authors Ann Brunson, MS, and Theresa Keegan, PhD, MS, discuss this and more with JAMA Oncology Web Editor, Vivek Subbiah, MD: ja.ma/49H6RJd

💬 Editorial: Metastatic recurrence nearly triples mortality risk in #BreastCancer among young adults and increases death risk in sarcoma and colorectal cancer—highlighting the need for earlier detection and novel treatments. ja.ma/43QeKbz